VRML remained flat at $$1.23 on Wednesday. The company had a trading volume of 71,682 shares, compared to its average volume of 65,516. Vermillion has a 12-month low of $0.27 and a 12-month high of $1.57. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.27 and a quick ratio of 3.61.
Vermillion (NASDAQ:VRML) last posted its earnings results on Thursday, March 28th. The company reported ($0.04) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Vermillion had a negative return on equity of 150.34% and a negative net margin of 381.57%. The firm had revenue of $0.92 million during the quarter.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Birchview Capital LP increased its position in Vermillion by 0.4% in the 1st quarter. Birchview Capital LP now owns 2,121,933 shares of the company’s stock worth $2,440,000 after buying an additional 8,000 shares during the period. Morgan Stanley increased its position in Vermillion by 390.2% in the 1st quarter. Morgan Stanley now owns 25,000 shares of the company’s stock worth $29,000 after buying an additional 19,900 shares during the period. Greenwich Wealth Management LLC increased its position in Vermillion by 11.3% in the 4th quarter. Greenwich Wealth Management LLC now owns 241,121 shares of the company’s stock worth $72,000 after buying an additional 24,500 shares during the period. Magnus Financial Group LLC bought a new position in Vermillion in the 1st quarter worth approximately $35,000. Finally, B. Riley Wealth Management Inc. increased its position in Vermillion by 38.4% in the 4th quarter. B. Riley Wealth Management Inc. now owns 182,245 shares of the company’s stock worth $55,000 after buying an additional 50,545 shares during the period. Hedge funds and other institutional investors own 20.92% of the company’s stock.
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
See Also: What is the Fibonacci sequence?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.